相关临床试验
10
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
20.0%
已完成
6
60.0%
Enrolling By Invitation
1
10.0%
招募中
1
10.0%
暂无批准数据
- Shape Memory Medical closed a $10 million convertible note financing led by August Global Partners, with Taiwania Capital also participating as a new investor. - The funding supports the AAA-SHAPE Pivotal Trial, the first randomized controlled pivotal trial testing proactive aneurysm sac embolization at the time of endovascular aneurysm repair (EVAR). - AAA-SHAPE randomized 180 patients 2:1 across 48 centers in the U.S., Europe, and New Zealand, with primary endpoints of 30-day safety and at least 10% sac volume reduction without AAA-related reintervention at one year. - The company's IMPEDE-FX RapidFill device remains investigational for the aortic indication in the U.S., while its shape memory polymer technology has been used in more than 3,500 patients worldwide.
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients. - DETOUR2 study reveals the durability of percutaneous transmural arterial bypass with the DETOUR System for complex femoropopliteal disease, showing promising 3-year outcomes. - SIRONA trial's post-hoc analysis suggests sirolimus-coated balloons as a viable alternative to paclitaxel-coated balloons in femoropopliteal angioplasty. - ELEGANCE registry indicates that drug-eluting devices in endovascular PAD treatment yield excellent 1-year outcomes in underrepresented patient groups.
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients. - DETOUR2 study shows percutaneous transmural arterial bypass with the DETOUR System offers durable outcomes for complex femoropopliteal lesions at three years. - The LIFE-BTK trial indicates the Global Limb Anatomic Staging System (GLASS) effectively identifies CLTI patients at higher risk for adverse events.
